About The Study: A longitudinal analysis of 42,000 National Health and Nutrition Examination Survey participants and meta-analysis found higher bone lead levels associated with significantly increased cardiovascular disease mortality risk. Globally in 2023, 3.5 million deaths and 71.6 million disability-adjusted life-years (DALYs) were attributable to lead exposure, accounting for 5.8% of all deaths and 2.6% of all DALYs. Strengthened surveillance, regulation, and remediation are urgently required to reduce the lead-attributable burden.

About The Study: Extended low-intensity anticoagulation with apixaban was associated with a reduction in symptomatic superficial vein thrombosis (SuVT) in patients with provoked venous thromboembolism with enduring risk factors for recurrence. Further randomized clinical trials specifically focused on SuVT are needed to ascertain optimal antithrombotic strategies in broader populations at risk of SuVT.

About The Study: After multivariable adjustment, serum neurofilament light chain (sNfL) levels were associated with a broad range of adverse cardiovascular events and mortality in patients with atrial fibrillation (AF). Serum NfL may serve as a biomarker of cardiovascular risk in patients with AF.

About The Study: The results of this post hoc analysis of the Finerenone Trial to Investigate the Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) randomized clinical trial reveal that in this contemporary heart failure with mildly reduced ejection fraction or heart failure with preserved ejection fraction cohort, sudden death was preceded by modest worsening of symptoms, declining quality of life, and rising natriuretic peptide levels, suggesting many of these events may not have been entirely sudden. However, similar deterioration preceding other modes of death suggests limited specificity for sudden death.